Compare Apple Inc (AAPL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Novo Nordisk A/S — how do they compare? Apple Inc trades at $312.48 (market cap $4.56T), while Novo Nordisk A/S trades at $49.21 (market cap $220.20B). The key difference: Apple Inc is far larger — about 20.7× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| AAPL | NVO | |
|---|---|---|
Market Cap | $4.56T | $220.20B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $71.70 |
52-Week Low | $202.38 | $35.29 |
Enterprise Value | $4.58T | $239.16B |
Dividend Yield | 0.35% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $310.09, down 0.82% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding the $1.95 estimate. Revenue for 2025 reached $416.16 billion, driving a net income margin of 26.91%. Analysts maintain a consensus buy rating with a $329.62 price target, citing Apple's massive device base as an AI opportunity.
The outlook remains positive given earnings momentum and a $0.27 dividend, but risks include potential Q2 2026 earnings miss concerns and union disputes. Valuation multiples like P/E of 37.61 suggest premium pricing, requiring sustained growth to justify upside. Institutional holdings show mixed activity, with some trimming positions amid high RSI levels indicating overbought conditions near-term.
Novo Nordisk (NVO) trades at $49.64, down 1.57% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with $309.1B revenue in 2025 and impressive profitability metrics including 37.2% net income margin and 71.4% ROE. Recent earnings beats and Medicare's GLP-1 coverage expansion for weight-loss drugs provide positive catalysts. Analyst consensus remains strongly bullish with 22 buy ratings versus only 3 sell recommendations.
NVO presents a compelling investment case with strong earnings growth, market leadership in GLP-1 therapies, and favorable valuation at 11.82 P/E. Key risks include intensifying competition in obesity drugs and potential pricing pressures. The stock's current technical setup near support at $49 suggests potential for rebound, supported by institutional confidence and positive business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
